Table 1.
Questionnaire descriptive statistics and internal consistency reliability estimates for the prostate and testicular cancer survivor subsamples
| PCa Survivors | TCa Survivors | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Questionnaire scales | N | M | SD | % floor/ ceiling | Cronbach’sα | N | M | SD | % floor/ ceiling | Cronbach’s α |
| SF-36 | ||||||||||
| Physical Functioning | 112 | 73 | 27 | 0.93 | 124 | 92 | 15 | 52c | 0.91 | |
| Role-Physical | 113 | 61 | 44 | 50c | 0.91 | 125 | 89 | 26 | 77c | 0.86 |
| Bodily Pain | 116 | 68 | 26 | 26c | 0.91 | 126 | 85 | 21 | 56c | 0.93 |
| General Health | 116 | 64 | 20 | 0.77 | 125 | 74 | 21 | 0.80 | ||
| Vitality | 114 | 64 | 20 | 0.82 | 123 | 66 | 19 | 0.82 | ||
| Social Functioning | 116 | 79 | 23 | 38c | 0.86 | 126 | 84 | 22 | 54c | 0.81 |
| Role-Emotional | 112 | 74 | 40 | 67c | 0.88 | 126 | 90 | 24 | 80c | 0.68 |
| Mental Health | 113 | 75 | 17 | 0.80 | 123 | 79 | 15 | 0.83 | ||
| IOCv2 | ||||||||||
| Altruism/empathy | 115 | 3.3 | 0.7 | 0.77 | 125 | 3.5 | 0.8 | 0.77 | ||
| Health awareness scale | 114 | 3.1 | 0.9 | 0.74 | 125 | 3.4 | 0.8 | 0.71 | ||
| Meaning of cancer scalea | 112 | 2.6 | 0.8 | 0.85 | 110 | 2.8 | 0.8 | 0.82 | ||
| Positive self-evaluation | 115 | 3.3 | 0.7 | 0.64 | 126 | 3.5 | 0.8 | 0.69 | ||
| Positive Impact Score | 115 | 3.1 | 0.5 | 0.82 | 126 | 3.3 | 0.6 | 0.87 | ||
| Appearance concerns | 114 | 1.8 | 0.7 | 25f | 0.73 | 124 | 1.9 | 0.9 | 33f | 0.83 |
| Body change concerns | 115 | 2.6 | 1.0 | 0.81 | 124 | 2.2 | 0.9 | 0.77 | ||
| Life interferences | 115 | 2.1 | 0.7 | 0.75 | 126 | 1.8 | 0.8 | 21f | 0.85 | |
| Worry | 115 | 2.4 | 0.9 | 0.90 | 125 | 2.4 | 0.9 | 0.90 | ||
| Negative Impact Score | 115 | 2.2 | 0.7 | 0.93 | 126 | 2.1 | 0.7 | 0.94 | ||
| Employment concernsb | 132 | 2.7 | 1.1 | 0.63 | 111 | 2.1 | 0.9 | 23f | 0.74 | |
| Relationship/not partnered concerns | 25 | 2.3 | 0.9 | 0.82 | 24 | 2.2 | 1.1 | 25f | 0.85 | |
| Relationship/partnered concerns | 92 | 1.8 | 0.6 | 22f | 0.52 | 102 | 1.5 | 0.6 | 39f | 0.62 |
| QLQ-C30 | ||||||||||
| Global health status/QoL | 112 | 69 | 20 | 0.96 | 124 | 79 | 19 | 22c | 0.92 | |
| Physical Function | 113 | 84 | 18 | 30c | 0.83 | 126 | 95 | 12 | 68c | 0.82 |
| Role Function | 114 | 85 | 24 | 61c | 0.90 | 126 | 94 | 17 | 84c | 0.93 |
| Emotional Function | 113 | 85 | 18 | 40c | 0.84 | 124 | 86 | 17 | 39c | 0.84 |
| Cognitive Function | 114 | 83 | 21 | 44c | 0.73 | 124 | 91 | 16 | 66c | 0.61 |
| Social Function | 114 | 88 | 20 | 61c | 0.78 | 124 | 94 | 16 | 82c | 0.86 |
| Fatigue | 114 | 22 | 21 | 28f | 0.84 | 126 | 21 | 21 | 33f | 0.85 |
| Nausea/vomitingc | 114 | 1 | 5 | 91f | −0.04 | 126 | 2 | 6 | 87f | – |
| Pain | 114 | 18 | 25 | 53f | 0.89 | 126 | 12 | 20 | 63f | 0.85 |
| Dyspnoead | 114 | 15 | 22 | 63f | – | 125 | 9 | 18 | 75f | – |
| Insomniad | 113 | 18 | 29 | 65f | – | 126 | 13 | 22 | 68f | – |
| Appetite lossd | 113 | 5 | 17 | 91f | – | 126 | 4 | 14 | 89f | – |
| Constipationd | 114 | 11 | 21 | 75f | – | 120 | 5 | 14 | 87f | – |
| Diarrhoead | 113 | 7 | 18 | 83f | – | 124 | 6 | 17 | 85f | – |
| Financial problemsd | 114 | 5 | 18 | 90f | – | 123 | 8 | 21 | 86f | – |
| QLQ-PR25 | ||||||||||
| Sexual activity | 112 | 26 | 25 | 32 f | 0.67 | – | – | – | – | – |
| Sexual functioning | 43 | 51 | 20 | 0.41 | – | – | – | – | – | |
| Urinary problems | 115 | 22 | 20 | 0.89 | – | – | – | – | – | |
| Incontinence aid problemsd | 49 | 29 | 34 | 49 f | – | – | – | – | – | – |
| Bowel problems | 108 | 8 | 14 | 52 f | 0.79 | – | – | – | – | – |
| Treatment related symptoms | 112 | 13 | 12 | 0.45 | – | – | – | – | – | |
| QLQ-TC26 | ||||||||||
| Satisfaction with care | – | – | – | – | – | 111 | 80 | 28 | 52c | 0.85 |
| Future perspective | – | – | – | – | – | 125 | 77 | 24 | 36c | 0.56 |
| Communication | – | – | – | – | – | 125 | 76 | 25 | 34c | 0.53 |
| Sexual activity | – | – | – | – | – | 121 | 60 | 27 | 0.77 | |
| Sexual enjoyment | – | – | – | – | – | 116 | 76 | 25 | 38c | 0.77 |
| Satisfaction with testicular implantd | – | – | – | – | – | 35 | 55 | 37 | 31c | – |
| Treatment side effects | – | – | – | – | – | 125 | 11 | 12 | 28f | 0.63 |
| Job problems | – | – | – | – | – | 125 | 15 | 26 | 66f | 0.82 |
| Sexual problems | – | – | – | – | – | 115 | 13 | 22 | 65f | 0.59 |
| Family problemsd | – | – | – | – | – | 125 | 15 | 28 | 70f | – |
| Infertilityd | – | – | – | – | – | 123 | 24 | 34 | 58f | – |
| Body Imaged | – | – | – | – | – | 125 | 18 | 28 | 62f | – |
| QPSNordic | ||||||||||
| Work Motivation | – | – | – | – | – | 113 | 3.8 | 0.7 | 0.42 | |
| Job and life satisfaction | – | – | – | – | – | 113 | 3.9 | 0.8 | 0.71 | |
| Work ability | – | – | – | – | – | 113 | 3.8 | 0.8 | 0.82 | |
| Self-efficacy | – | – | – | – | – | 113 | 4.4 | 0.8 | 40c | 0.83 |
Scale range for the SF-36, QLQ-C30, QLQ-PR25 and QLQ-TC26 is from 0 to 100. The IOCv2 and QPS Nordic scale range from 1 to 5. For the function scales and global health scale of the EORTC-QLQC30 and its modules a higher score represents a better level of functioning. For the symptom oriented scales and items higher scores indicate a higher level of symptoms; Percentage floor or ceiling effects are only reported when they exceed 20%.; TCa testicular cancer survivors, PCa prostate cancer survivors, N number of participants, M mean, SD standard deviation, c ceiling, f floor
aDue to a mistake in the Norwegian version of the IOCv2 14 respondents skipped more than half of the items of this scale
bN is higher than the number of respondents who were actually employed, since the item was also completed by some participants who were retired
cReliability of the NV scale could not be calculated do to the very low prevalence of nausea and the absence of vomiting in the TCa sample
dSingle item scales